This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
Ketorolac tromethamine injection, a nonsteroidal anti-inflammatory drug, is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
Cross-sectional data from the National Health and Nutrition Examination Survey from 1988 to 1994 and 1999 to 2016 were used for this analysis.
The FDA has received reports of tranexamic acid injection being erroneously administered intrathecally in the perioperative setting instead of the intended intrathecal anesthetic (eg, bupivacaine injection) for neuraxial anesthesia.
Xaracoll® (bupivacaine HCl; Innocoll Pharmaceuticals Limited) implant is now available for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair. Xaracoll is a bioresorbable collagen-matrix implant designed to deliver bupivacaine HCl to the surgical site. Each implant contains 100mg of bupivacaine HCl (equivalent to 88.8mg bupivacaine) and 75mg…
The use of NSAIDs after 20 weeks of pregnancy may lead to low levels of amniotic fluid surrounding the baby resulting in kidney complications.
Treatment also linked to more serious adverse events.
The approval was based on data from 2 placebo-controlled phase 3 studies that evaluated the efficacy and safety of XaraColl for postoperative pain in 610 adults scheduled for open inguinal hernia surgery.
The safety of long-term Orphengesic Forte use has not been established.
This guideline provides recommendations for managing acute pain resulting from non–low back, musculoskeletal injuries in adults.
